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Abstract
Background: XIAP (X-linked inhibitor of apoptosis protein) is one of the most important members of the apoptosis inhibitor
family. XIAP is upregulated in various malignancies, including human glioblastoma. It promotes invasion, metastasis, growth
and survival of malignant cells. We hypothesized that downregulation of XIAP by human umbilical cord blood mesenchymal
stem cells (hUCBSC) in glioma cells would cause them to undergo apoptotic death.
Methodology/Principal Findings: We observed the effect of hUCBSC on two malignant glioma cell lines (SNB19 and U251)
and two glioma xenograft cell lines (4910 and 5310). In co-cultures of glioma cells with hUCBSC, proliferation of glioma cells
was significantly inhibited. This is associated with increased cytotoxicity of glioma cells, which led to glioma cell death. Stem
cells induced apoptosis in glioma cells, which was evaluated by TUNEL assay, FACS analyses and immunoblotting. The
induction of apoptosis is associated with inhibition of XIAP in co-cultures of hUCBSC. Similar results were obtained by the
treatment of glioma cells with shRNA to downregulate XIAP (siXIAP). Downregulation of XIAP resulted in activation of
caspase-3 and caspase-9 to trigger apoptosis in glioma cells. Apoptosis is characterized by the loss of mitochondrial
membrane potential and upregulation of mitochondrial apoptotic proteins Bax and Bad. Cell death of glioma cells was
marked by downregulation of Akt and phospho-Akt molecules. We observed similar results under in vivo conditions in
U251- and 5310-injected nude mice brains, which were treated with hUCBSC. Under in vivo conditions, Smac/DIABLO was
found to be colocalized in the nucleus, showing that hUCBSC induced apoptosis is mediated by inhibition of XIAP and
activation of Smac/DIABLO.
Conclusions/Significance: Our results indicate that downregulation of XIAP by hUCBSC treatment induces apoptosis, which
led to the death of the glioma cells and xenograft cells. This study demonstrates the therapeutic potential of XIAP and
hUCBSC to treat malignant gliomas.
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Introduction
Apoptosis is the cell’s intrinsic death program that controls
normal tissue homeostasis. Apoptosis pathways can be initiated
through death receptors or mitochondria and usually result in
activation of caspases as common effector molecules [1]. Evasion of
apoptosis is one of the hallmarks of human cancers, including
glioblastoma [2]. One mechanism through which tumor cells are
believed to acquire resistance to apoptosis is by overexpression of
XIAP (X-linked inhibitor of apoptosis protein). XIAP has received
interest as a therapeutic targetas it is probably the IAP member best
characterized with respect to structure and biochemical mechanism
[3–5]. XIAP interacts with and inhibits active caspases-3, -7 and -9
[6–8]. Recent studies confirmed that overexpression of XIAP
confers resistance to multi-agent chemotherapy, including stimuli of
the mitochondrial and death receptor pathways of caspase
activation [9–11]. Through its ability to inhibit caspases, overex-
pression of XIAP renders cells resistant to multi-agent chemother-
apy. XIAP is frequently overexpressed in malignant cells and, in
certain patients, is associated with poor clinical outcome [12].
Knocking out XIAP with siRNA or antisense oligonucleotides
restores chemosensitivity to a variety of malignant cell lines [13–16].
Characterization of XIAP-deficient mice proved that knocking out
XIAPisnottoxictonormal cellsasevidencedbya lackofsignificant
pathology in the XIAP knockout mouse [17]. However, there have
been very few reports of the downregulation of XIAP in human
glioblastoma cells.
Human umbilical cord blood is an alternative source of adult
stem cells. Several reports indicate that human umbilical cord
blood derived mesenchymal stem cells (hUCBSC) are similar to
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and multilineage differentiation potential [18–20]. Recently,
hUCBSC were proved to be more advantageous in cell
procurement, storage, and transplantation than bone marrow–
derived mesenchymal stem cells [21]. These hUCBSC were used
to induce cytotoxicity in malignant glioma cells [22] and to show
their migration capacity towards glioma cells [23]. Under in vivo
conditions, TRAIL-secreting hUCBSC were used against intra-
cranial gliomas [24]. However, the mechanistic aspects of
hUCBSC against apoptosis induction in glioma have not been
well established.
Hence, in the present study, we investigated the effects of both
hUCBSC and siXIAP (shRNA for XIAP) in the downregulation of
XIAP and thus inducing apoptosis in glioblastoma cells both in vitro
and in vivo. We observed that downregulation of XIAP in glioma
cells induced apoptosis involving mitochondria. This has been
correlated with mitochondrial membrane potential damage and
inhibition of survival and proliferation of glioma cells. In addition,
we evaluated the in vivo effects of hUCBSC against glioma
xenografts for the induction of apoptosis and pathway specific
proteins.
Results
Co-culture of glioma cells with hUCBSC downregulates
XIAP
For all the experiments of this study we used hUCBSC which
are positive for CD29 and CD81 (data not shown). To evaluate the
efficiency of hUCBSC, we tested the effect of hUCBSC on glioma
cells in co-cultures for 3 days. In order to make sure that inhibition
of cell proliferation, induced cytotoxicity, observed apoptotic
phenotype and decreased protein expressions of XIAP and Akt in
glioma cells, the co-cultures were grown in the same media which
was used for growing glioma cells alone, as described in Materials
and Methods. We performed MTT assay and cytosolic LDH
cytotoxicity assays to study the effect of hUCBSC on the glioma
cells. We observed that hUCBSC inhibited proliferation of the
glioma cell lines and the inhibition was more than 50% in all the
cell lines tested (Fig. 1A). Also, cytotoxicity induced by hUCBSC
was significant (p,0.05) and more than 50% in all the cell lines
(Fig. 1B). Xenograft cell lines 5310 and 4910 were found to have
more cytotoxicity than glioma cell lines SNB19 and U251. We
next tested whether or not this cytotoxicity resulted in the cell
death or not. For this, we ran FACS analyses of all the single and
co-cultures of cell lines using Annexin V. All the glioma cell lines in
co-culture with hUCBSC were found to have more than 50%
apoptotic cells (Fig. 1C). In order to check the expression of
apoptotic proteins, we ran immunoblot analysis of XIAP, Akt and
pAkt molecules, which are highly upregulated in glioma cells. As
expected, XIAP was highly downregulated in all the co-cultures of
glioma cells (Fig. 1D). The downregulation of XIAP was correlated
with the downregulation of Akt and pAkt
S473. As a control
experiment to evaluate the effect of hUCBSC on glioma cells, we
co-cultured glioma cells with normal human astrocytes and
observed the effect of astrocytes on glioma cells. Astrocytes did
not show any effect on the status of XIAP, Akt and phospho-Akt in
the glioma cells (Fig. 1E). These results suggest that hUCBSC are
efficiently inducing cytotoxicity and apoptosis in order to inhibit
Figure 1. Growth inhibition of glioma cells by hUCBSC. (A) MTT assay of single and co-cultures of glioma cells with hUCBSC. Even though
proliferation values of both single cultures of glioma cells and hUCBSC were taken as 100%, values of proliferation of glioma + hUCBSC cocultures
were calculated in relation to single cultures of glioma alone. When we calculated values of proliferation of glioma + hUCBSC cocultures in relation to
single cultures of hUCBSC, we got much less values compared to the values presented here. (B) Cytotoxicity assay based on cytosolic LDH assay. (C)
FACS analysis results of glioma cells showing apoptotic cells as measured by Annexin V. Immunoblot analysis of proteins showing expression of XIAP,
Akt and pAkt
Ser473 in (D) single and co-cultures of glioma cells with hUCBSC and (E) single and co-cultures of glioma cells with astrocytes. 40 mgo f
proteins were loaded onto 12% gels and transferred onto nitrocellulose membranes and probed with respective antibodies. Immunoreactive bands
were visualized using chemiluminescence ECL Western blotting detection reagents and the reaction was detected using Hyperfilm-MP
autoradiography film. Each experiment was repeated 3 times. Error bars indicate 6SEM. * Significant at p,0.05.
doi:10.1371/journal.pone.0011813.g001
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phosphorylated form of Akt. To confirm that downregulation of
XIAP results in the inhibition of phosphorylation of Akt, the
glioma cells were transfected with shRNA of XIAP (siXIAP). In all
four of the cell lines, siXIAP inhibited proliferation (Fig. S1A),
induced cytotoxicity (Fig. S1B), and induced apoptosis in a
significant manner (p,0.05) (Fig. S1C). We routinely checked for
the expression of XIAP in cells transfected with siXIAP; XIAP was
highly silenced resulting in the decrease in the phosphorylation of
Akt in cells treated with siXIAP as compared to scrambled vector
(SV) (Fig. S2). These results confirm that co-culture with hUCBSC
and siXIAP treatment of glioma cells inhibits growth and
proliferation of glioma cells by inducing cytotoxicity and apoptosis
by downregulating XIAP. Further, to evaluate the process of
apoptosis, we performed TUNEL analysis of the cells co-cultured
with hUCBSC or treated with siXIAP. Both these treatments
induced significant apoptosis in glioma cells (p,0.05) (Fig. 2A) as
compared to control and SV treatments. However, when
compared to hUCBSC treatments, siXIAP treatments induced
apoptosis in greater number of cells (Figs. 2B and 2C). In order to
confirm the time period at which hUCBSC show their effect on
glioma cells, we did time-course experiments. Glioma cells were
Figure 2. Evaluation of apoptosis of glioma cells by TUNEL assay. (A) Single and co-cultures of glioma cells and hUCBSC and siXIAP-
transfected glioma cells were seeded in 8-well chamber slides. After various treatments, TUNEL assay was done using in situ cell death detection kit
(Roche) as per the manufacturer’s protocol. (B) Quantitative estimation of TUNEL cells in hUCBSC treatments. (C) Quantitative estimation of TUNEL
cells in siXIAP treatments. Each experiment was repeated 3 times. The results show a significant increase in the number of apoptotic cells with siXIAP
and hUCBSC treatments as compared to the control and SV treatments. Inset pictures show DAPI. SV=scrambled vector. n=3. * Significant at
p,0.05.
doi:10.1371/journal.pone.0011813.g002
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and 72 h) and the cell lysates were analyzed by immunoblot
analysis. In both U251 and 5310 cell lines of the present study,
72 h period was found to be more effective in inhibiting XIAP and
Akt and inducing apoptosis in glioma cells (Fig. S3).
To identify the molecular mechanisms that underlie the induced
apoptosis in glioma cells treated with hUCBSC and siXIAP, we
focused on the Bcl-2 family of apoptosis regulators that integrate
cellular survival and apoptotic signals through their action on
mitochondria. We reasoned that both hUCBSC and siXIAP might
activate pro-apoptotic members of the Bcl-2 family (e.g., Bax) in
order to allow the glioma cells to undergo apoptosis. For this, we
assessed immunoblots of pro-apoptotic proteins Bax and Bad.
Both Bax and Bad proteins were highly upregulated and
associated with a decrease in the expression of Bcl-2 protein in
hUCBSC treatments compared to single cultures of glioma cells
(Fig. 3A). Similar results were observed in siXIAP treatments
compared to control and SV treatments (Fig. S2). These results
confirm that in both the treatments, Bax and Bad were highly
upregulated, thereby confirming the involvement of mitochondria
during apoptotic induction. Increasing evidence suggests that
altered mitochondrial function is linked to apoptosis, and a
decreasing mitochondrial transmembrane potential is associated
with mitochondrial dysfunction [25]. Hence, we tested whether
upregulation of Bax and Bad is correlated with damage to
mitochondrial membrane potential in these glioma cells. In
hUCBSC treatments, SNB19 cells showed the highest percentage
(84.17%) of mitochondrial membrane potential damage followed
by 5310 (59.33%), 4910 (59.19%) and U251 (58.68%) (Fig. 3B).
On the other hand, in siXIAP treatments, the highest mitochon-
drial membrane potential damage was observed in 4910 (71.91%)
followed by 5310 (71.67%), U251 (66.96%) and SNB19 (64.28%)
(Fig. 3C). These results confirm that the hUCBSC and siXIAP
treatments induced upregulation of Bax and Bad to involve
mitochondria in apoptosis, and this is significantly associated with
mitochondrial membrane potential damage in all the glioma cells
Figure 3. Downregulation of XIAP induces mitochondrial apoptosis. Immunoblot analysis of proteins showing expression of (A) Bax, Bad
and Bcl-2 in co-cultures of glioma cells with hUCBSC treatments. 40 mg of proteins were loaded onto 14% gels, transferred onto nitrocellulose
membranes and probed with respective antibodies. Immunoreactive bands were visualized using chemiluminescence ECL Western blotting
detection reagents and the reaction was detected using Hyperfilm-MP autoradiography film. Mitochondrial membrane potential damage was
evaluated using Mitotracker red (Invitrogen). (B) Shows mitochondrial membrane potential damage in co-cultures and (C) in siXIAP treatments. Each
experiment was repeated 3 times. SV=scrambled vector. Error bars indicate 6SEM. * significant at p,0.05.
doi:10.1371/journal.pone.0011813.g003
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hypothesis that co-cultures of glioma cells with hUCBSC induced
apoptosis involving mitochondria, ultimately leading to death of
the glioma cells, and the action of hUCBSC is similar to silencing
of XIAP.
Further, we evaluated whether or not downregulation of XIAP
in glioma cells activates the caspase enzymes leading to apoptosis.
We measured caspase-3 activity in glioma cells alone and in co-
culture with hUCBSC. Co-culture of hUCBSC activated caspase-
3 enzyme in a significant manner in the glioma cells (p,0.05)
(Fig. 4A). For this assay, we also used human astrocytes alone and
in co-culture with hUCBSC. Contrary to glioma cells, hUCBSC
did not activate caspases in astrocytes. In a similar way, we also
tested the activity of caspase-9 since this enzyme is related to
mitochondrial apoptosis. Co-cultures of hUCBSC with glioma
cells show higher activity of caspase-9 whereas hUCBSC did not
induce any activity of caspase-9 in astrocytes (Fig. 4B). The
efficiency of these analyses was checked by the application of
inhibitors of caspase-3 and caspase-9 which showed reduced levels
of caspases. These results show that induction of apoptosis by
hUCBSC is exclusive to glioma cells only but not to normal cells
such as astrocytes. We also tested the siXIAP treatments for
inducing the activity of caspases and observed that both caspase-3
and caspase-9 are activated by siXIAP treatments (Fig. S4).
Further, to evaluate the effect of hUCBSC on glioma cells and
normal astrocytes, we tested the expression of pAkt (S
473) in the
cell lysates by immunoblot analyses. Expression of pAkt in U251
and 5310 cells was downregulated by hUCBSC in co-cultures
whereas in astrocytes, there was no effect on the expression pAkt
(Fig. 4C). However, Akt inhibitor IV downregulated phosphory-
lation of Akt in all 3 cell lines U251, 5310 and astrocytes. In
another experiment, we used Akt inhibitor IV for 309 to inhibit
phosphorylation of Akt in U251, 5310 and astrocytes and then co-
cultured them with hUCBSC for 3 days. In both glioma cell lines
U251 and 5310, pAkt levels were downregulated whereas in
astrocytes, they were brought back to the normal levels. That
means, even though Akt inhibitor IV inhibited the phosphoryla-
tion of Akt in astrocytes, co-culture with hUCBSC restored the
phosphorylation status of Akt in astrocytes alone. These results
confirm that inhibition of phosphorylation of Akt by hUCBSC is
exclusively restricted to only the glioma cells but not to normal
astrocytes. Rather, normal cells are restored to normal phosphor-
ylation levels of Akt by hUCBSC to enhance their growth and
proliferation. These results confirm our previous observations with
Figure 4. Activity of caspases in single and co-cultures of cells. (A) Caspase-3 activity in single and co-cultures of hUCBSC with glioma cells or
human astrocytes. (B) Caspase-9 activity in single and co-cultures of hUCBSC with glioma cells or human astrocytes. Both of these assays were done
as described in Materials and Methods. C3I= Caspase-3 Inhibitor (Ac-DEVD-CHO); C9I= Caspase-9 inhibitor (Ac-LEHD-CHO). Each experiment was
repeated 3 times. Error bars indicate 6SEM. * Significant at p,0.05. (C) Cell lysates of the respective treatments were immunoblotted and probed
with pAkt (S
473) and respective GAPDH. Akt inhibitor IV was used at a concentration of 10 mM per ml for 309 at 37uC and 5% CO2 in an incubator
(n=3).
doi:10.1371/journal.pone.0011813.g004
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protect cortical neurons against glutamate toxicity following Akt
pathway (56).
Downregulation of XIAP by hUCBSC treatment has an
anti-tumor effect in U251 and 5310 glioma nude mice
models
Our in vitro experiments have proven that co-cultures with
hUCBSC can efficiently inhibit glioma cell proliferation, causing
cytotoxicity and leading to apoptosis. Therefore, we further
investigated the anti-tumor effect of these stem cells in vivo using
U251 and 5310 cells in nude mice. After the mice were implanted
with U251, 5310 and hUCBSC as explained in Materials and
Methods, the mice were observed for 21 days. At that point, tumor
samples were taken, and paraffin-embedded sections were
prepared for immunohistopathological examination. Hematoxylin
and Eosin (H&E) staining of the in vivo sections clearly showed that
the tumors in hUCBSC-treated mice were inhibited significantly
and were one-third of the size of the tumors in control mice brains
(p,0.05) (Figs. 5A and 5B). Then, we checked for the induction of
apoptosis in hUCBSC-treated tumors by TUNEL assay. Sections
of nude mice brains treated with hUCBSC clearly show the
presence of more numbers of TUNEL cells indicating that the
tumor cells are undergoing apoptosis (Fig. 5C). Next, we evaluated
XIAP expression in nude mice brain tissue lysates by immuno-
blotting. The tissue lysates showed significant reduction of XIAP,
Akt and pAkt in hUCBSC-treated mice tumors (p,0.05) (Fig. 5D).
Figure 5. Induction of apoptosis in nude mice brain tumors by hUCBSC in vivo. Nude mice with pre-established intracranial human glioma
tumors (U251 or 5310) were treated with hUCBSC by intracranial injection (2610
5). Fourteen days after hUCBSC administration, the brains were
harvested, sectioned, and stained with Hematoxylin and Eosin (n=3). Bar =500 mm. (A) Inhibition of intracranial tumors by hUCBSC in vivo. (B)
Quantification of tumor size (n$3). Error bars indicate 6SEM. * Significant at p,0.05. (C) TUNEL analysis of control and hUCBSC treated sections. Bar
=200 mm. Immunoblot analysis of proteins showing expression of (D) XIAP, Akt and pAkt in tissue lysates of brains. (E) Quantitative estimation of (D).
40 mg of proteins were loaded onto 12% gels and transferred onto nitrocellulose membranes and probed with respective antibodies.
Immunoreactive bands were visualized using chemiluminescence ECL Western blotting detection reagents and the reaction was detected using
Hyperfilm-MP autoradiography film. Error bars indicate 6SEM. * Significant at p,0.05. (F) Reverse-transcription based PCR was run using cDNA from
control and tumor and hUCBSC-treated tumor brains and using XIAP and b-actin primers. (G) Detection of XIAP in nude mice brain sections by
Fluorescent in situ hybridization (FISH) analysis: Control and hUCBSC treated sections were processed for FISH analysis as explained in Materials and
Methods. Bar =200 mm.
doi:10.1371/journal.pone.0011813.g005
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significantly downregulated in hUCBSC treatments compared to
control tumors (Fig. 5E). Also, we ran reverse-transcription based
PCR to check the expression of XIAP in control tumor and
hUCBSC-treated tumor brain samples. In both the hUCBSC-
treated xenograft brains, XIAP levels were highly downregulated
(Fig. 5F). We further evaluated the expression of XIAP mRNA
by means of FISH analysis. Control tumor brain sections of
both U251 and 5310, which were probed with anti-sense XIAP
oligonucleotides, showed higher expression of XIAP mRNA
(Fig. 5G). Compared to these, hUCBSC-treated brain sections
showed very low expression of XIAP mRNA, proving the fact that
hUCBSC downregulate XIAP under in vivo conditions. These
results confirm our in vitro experiments that hUCBSC downreg-
ulate XIAP in the glioma cells.
In order to evaluate the mechanism by which apoptosis is
induced in the nude mice tumor brains, we carried out
immunohistochemistry on brain sections with cleaved caspase-3
antibody. Since XIAP is downregulated in the mice tumors, we
hypothesized that caspases should be active in these tumor
sections. As expected, caspase-3 was highly expressed in hUCBSC-
treated sections (Fig. 6A). We further evaluated the tissue lysates
using immunoblot analysis and observed that TNF-a, TRAIL and
cleaved PARP are highly upregulated in hUCBSC treatments
(Fig. 6B). In stem cell treatments, both caspase-3 and TNF-a were
significantly upregulated compared to control tumor brains
(p,0.05) (Fig. 6C). These results confirm that downregulation of
XIAP in mice tumor brains induces the activation of caspase-3,
which induced apoptosis. In both in vitro and in vivo experiments we
observed that the process of apoptosis was induced by the
activation of death ligand TRAIL (Fig. S2, Fig. S3 and Fig. 6).
Together, all these apoptotic proteins are involved in the cleavage
of PARP in the nucleus, thereby leading to cell death. Finally, we
checked whether mitochondria were involved in the process of
apoptosis in the mice tumor brains similar to the in vitro results. We
probed the tumor sections as well as hUCBSC-treated sections
with Bax antibody. We carried out co-localization studies with
CD81 (a mesenchymal stem cell marker for hUCBSC) and Bax
Figure 6. Upregulation of caspase-3 and Bax in nude mice brains. Nude mice with pre-established intracranial human glioma tumors (U251
or 5310) were treated with hUCBSC by intracranial injection (2610
5). Fourteen days after hUCBSC administration, the brains were harvested,
sectioned and immunoprobed for caspase 3 using appropriate HRP-conjugated secondary antibody. (A) Expression of cleaved caspase-3 activity in
brain sections. Bar =200 mm. (B) Immunoblot analysis of proteins showing expression of cleaved caspase 3, TNF-alpha, TRAIL and cleaved PARP in
tissue lysates of brains. (C) Quantitative estimation of (B). 40 mg of proteins were loaded onto 12–14% gels and transferred onto nitrocellulose
membranes and probed with respective antibodies. Immunoreactive bands were visualized using chemiluminescence ECL Western blotting
detection reagents and the reaction was detected using Hyperfilm-MP autoradiography film. (D) In vivo expression of Bax. Brain sections were
immunoprobed for Bax and CD81 using appropriate secondary antibodies. Bax is labeled with Alexa Fluor-594 conjugated secondary antibody and
CD81 is labeled with Alexa Fluor-488 conjugated secondary antibody. Bar =200 mm. (E) Immunoblot analysis of proteins showing expression of Bax
and Bad in tissue lysates of brains. 40 mg of proteins were loaded onto 14% gels and transferred onto nitrocellulose membranes and probed with
respective antibodies. Immunoreactive bands were visualized using chemiluminescence ECL Western blotting detection reagents and the reaction
was detected using Hyperfilm-MP autoradiography film. (F) Quantitative estimation of (E).
doi:10.1371/journal.pone.0011813.g006
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when compared to the control tumor brains. Further, Bax was co-
localized with CD81, confirming the presence of hUCBSC in
treated brains (Fig. 6D). These results were confirmed by
immunoblot analysis of Bax and Bad proteins in tissue lysates,
which showed highly elevated levels in the treated samples
(Fig. 6E). Quantification of Western bands shows that both Bax
and Bad were significantly upregulated in stem cell treatments
compared to control tumor sections (p,0.05) (Fig. 6F). Finally, we
tested the involvement of Smac/DIABLO in the induction of
apoptosis by hUCBSC. We performed co-localization experiments
with Smac/DIABLO and MTCO2 in the brain sections of both
treated and untreated samples. In control tumor brain sections,
Smac/DIABLO was co-localized in the mitochondria whereas in
hUCBSC-treated brain sections, Smac/DIABLO was co-localized
in the nucleus (Fig. 7). These results show that mitochondrial
apoptosis was involved in the hUCBSC-treated tumors. Taken
together, these results confirm the anti-tumor effect of hUCBSC in
vivo and that glioma cell apoptosis in vitro is efficiently induced by
hUCBSC by the downregulation of XIAP.
Discussion
Malignant gliomas are the most commonly diagnosed malig-
nant adult primary brain tumors. Resistance to induction of cell
death by apoptosis in response to radiotherapy or chemotherapy is
one of the hallmarks of many solid tumors, including glioblastoma.
These tumors overexpress XIAP. The principle mechanism
underlying the anti-apoptotic activity of XIAP has been proposed
to be direct caspase inhibition [26]. Many reports in cultured cells
have demonstrated that overexpression of XIAP confers resistance
to multi-agent chemotherapy, including stimuli of the mitochon-
drial and death receptor pathways of caspase activation [9–11].
Knocking out XIAP with siRNA or antisense oligonucleotides
restores chemosensitivity to a variety of malignant cell lines
[13–16]. Finally, knocking out XIAP is not toxic to normal cells, as
evidenced by a lack of significant pathology in the XIAP knockout
mouse [17]. Hence, in this study, we used hUCBSC as well as
siXIAP to downregulate XIAP, thereby inducing apoptosis in
glioma cells.
Co-culturing of glioma cells with hUCBSC resulted in the loss of
XIAP protein and the induction of cell death in the absence of
external death stimuli (Figs. 1–4), illustrating an essential survival
function of XIAP in glioma cells. In a similar manner, siRNA for
XIAP induced death in the absence of external death stimuli to
glioma cells. We observed that the depletion of XIAP led to the
activation and processing of caspases and the activation of Bad and
Bax proteins in the mitochondria to induce apoptosis. This is
further correlated with the downregulation of Akt and pAkt
molecules. Akt is overactivated in many glioblastomas due to the
loss of PTEN function [27,28]. Akt regulates the function of
numerous downstream signaling proteins involved in cell cycle,
proliferation, apoptosis and invasion, which are all important to
tumorigenesis [29]. Activated Akt deregulates cell growth by
stabilization of cyclin D and promotion of the nuclear entry of
mdm2, leading to the degradation of p53 [30]. On the other hand,
activated Akt exerts anti-apoptotic activity by phosphorylating and
inactivating pro-apoptotic signaling proteins, such as Bad and
caspase-9 [29,31]. Akt is one of the anti-apoptotic factors that must
be activated through phosphorylation. The involvement of Akt in
diverse tumorigenic activities suggests that Akt activation alone
might be sufficient to induce cancer [32].
In this study, XIAP downregulation is correlated with the
downregulation of Akt in both the treatments, suggesting that
these treatments inhibit the activation of Akt, which inhibits the
growth and survival of glioma cells. Recently, it was proposed that
XIAP acts as an E3 ubiquitin ligase for PTEN and promotes Akt
activity by regulating PTEN content and compartmentalization
[33]. In accordance with this report, previously we have shown
that hUCBSC upregulated PTEN while downregulating XIAP
[59]. Our present results are in accordance with the previous
reports, and downregulation of XIAP did result in the downreg-
ulation of Akt and inhibition of glioma cell growth, while inducing
apoptosis.
An alternative mechanism mediating XIAP-dependent protec-
tion from apoptosis involves transcriptional activity mediated via
the stimulation of NF-kB, which depends on the E3 ubiquitin
ligase activity of the RING domain of XIAP [34]. NF-kBi s
composed of two subunits, p65relA and p50, which are members
of the REL protein family. There are different pathways by which
NF-kB can be activated; cytokines such as tumor necrosis factor-a
(TNF-a) activate their receptor, and in turn recruit the complex of
inhibitor of kB( I kB) kinase (IKK), resulting in IKK phosphor-
ylation. IKK kinases include members of the mitogen-activated
protein kinase (MAPK) family, such as NF-kB-inducing kinase
(NIK) [35]. In the present study, we observed that hUCBSC
Figure 7. Co-localization of Smac/DIABLO in treated and untreated brain tumors. Nude mice with pre-established intracranial human
glioma tumors (U251 or 5310) were treated with hUCBSC by intracranial injection (2610
5). Fourteen days after hUCBSC administration, the brains
were harvested, sectioned and immunoprobed for Smac/DIABLO (second mitochondria-derived activator of caspase/direct IAP binding protein with
low PI) and MTCO2 (Mitochondrial Cytochrome Oxidase subunit 2 – mitochondrial marker) using appropriate HRP-conjugated secondary antibodies.
Smac/DIABLO is Alexa Fluor-488 conjugated and MTCO2 is Alexa Fluor-594 conjugated. Bar =200 mm.
doi:10.1371/journal.pone.0011813.g007
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simultaneously activates both the NF-kB-activated and caspase-
mediated apoptotic pathways. Recently, it was shown that TRAIL
kills malignant glioma cells through induction of apoptosis,
providing a new therapeutic strategy for these tumors [36–38].
It was suggested that TRAIL may induce activation of intrinsic
mitochondrial pathways, which may amplify and rescue TRAIL
receptor-mediated caspase 8-initiated activation of the caspase
cascade in the extrinsic pathway [37]. Local delivery of soluble
TRAIL [39], TRAIL-expressing adenoviral vector [24] and
TRAIL-secreting neural stem cells [40] have all been shown to
induce apoptosis in intracranial gliomas. Systemic administration
of soluble TRAIL along with chemotherapeutic drugs inhibits
glioma growth without causing neurological impairment or
damage to normal tissue in mice [41]. Our study shows that, in
glioma cells as well as in nude mice brain tumors, hUCBSC
induced TRAIL activation, which ultimately resulted in the
induction of apoptosis.
It has been demonstrated that induction of apoptosis requires
involvement of the Bcl-2 family including apoptosis inhibiting gene
products (e.g., Bcl-2, Bcl-XL) and apoptosis accelerating gene
products (e.g., Bad, Bax, Bak, Bcl-XS, Bim) [42,43]. The
susceptibility of tumor cells to induction of apoptosis is controlled
by the ratio between pro-apoptotic and anti-apoptotic proteins
such as Bax/Bcl-2 [44]. It has been reported that Bax is associated
with apoptotic cell death [45,46]. During apoptosis, Bax is
translocated to the mitochondria where it promotes the release
of proteins from the intermembrane space into cytoplasm, an
important step in apoptosis. Bax also interacts with the
permeability transition pore to facilitate protein movement
through the mitochondrial membrane [25,47,48]. Our results
indicate a critical role of XIAP in modulating the ratio of Bcl-2/
Bax and increased Bax protein expression in mediating apoptosis
in glioma cells. These changes ultimately led to the activation of
downstream caspases (caspases-9 and -3) and eliciting an apoptosis
response. In the present study, in both in vitro and in vivo systems,
hUCBSC increased Bax and Bad expression. Thus, induction of
apoptosis by hUCBSC involves Bax and Bad, which explains the
role of mitochondria in cell death. A decrease in mitochondrial
membrane potential plays an important role in cell death [49–51].
However, the role of mitochondrial membrane potential in cell
death induced by stem cells remains unclear. In the present study,
both hUCBSC and siXIAP treatments caused significant reduc-
tion in mitochondrial membrane potential before the induction of
cell death. This might result in mitochondrial depolarization
through the inhibition of respiratory chain [52]. Our results clearly
establish inhibition of XIAP functions as a potential way to
sensitize glioma cells to apoptosis.
Since XIAP inhibits both initiator and effector caspases, in the
present study hUCBSC downregulated XIAP which resulted in
the activation of caspases. Caspases play a key role during the
execution phase in various forms of apoptosis [53]. To evaluate the
role of caspase activation in the hUCBSC-induced cell death of
glioma cells, the effect of caspase inhibitors on hUCBSC-induced
cell death was examined. In this report, we demonstrated that
hUCBSC induced the activation of both caspase-9 and caspase-3.
Activation of the caspase-9/Apaf-1/cytochrome c apoptosome in
the mitochondrial-dependent apoptotic pathway leads, in turn, to
caspase-3 activation [54]. Hence, it is plausible that during the
induction of apoptosis by hUCBSC, mitochondrial upregulated
Bax and Bad induce the activation of caspase-9 in glioma cells
which ultimately triggers the activation of caspase-3, ultimately
leading to the apoptotic death by the cleavage of PARP. Here, we
have demonstrated that this particular induction of the activity of
caspases is restricted to glioma cells only and not to normal cells
such as astrocytes. In our study, we observed that apoptosis in
hUCBSC-treated nude mice tumor brains was carried out by the
upregulation of TRAIL and TNF-a. TRAIL belongs to the TNF
cytokine family and is capable of inducing apoptosis in a variety of
cancer cells, while producing negligible effects on normal cells
[55]. Our results show that hUCBSC are able to activate both
apoptotic mechanisms mediated by caspase-3 as well as TRAIL,
which ultimately inhibits the growth of the tumors by inducing
apoptosis. Finally, the localization of Smac/DIABLO in the
nucleus of the hUCBSC-treated brain sections is a clear indication
of apoptosis taking place in the treated brains.
In conclusion, the growth retardation of glioblastoma cells
treated with hUCBSC is not only due to the induction of apoptosis
via caspase activation but also due to the downregulation of Akt
and the involvement of mitochondrial apoptotic factors. Targeting
XIAP by using hUCBSC might be an effective new strategy for the
potential therapy of human gliomas.
Materials and Methods
Ethics Statement
After obtaining informed consent, human umbilical cord blood
was collected from healthy volunteers according to a protocol
approved by the Peoria Institutional Review Board, Peoria, IL,
USA. The consent was written and approved. The approved
protocol number is 06-014, dated December 10, 2009. The
Institutional Animal Care and Use Committee of the University
Of Illinois College Of Medicine at Peoria, Peoria, IL, USA
approved all surgical interventions and post-operative animal care.
The consent was written and approved. The approved protocol
number is 851, dated November 20, 2009.
Cell Cultures
Two high-grade human glioma cell lines SNB19 and U251 and
two xenograft cell lines 4910 and 5310 were used for this study.
SNB19 and U251 cells lines were obtained from American Type
Culture Collection (ATCC, Manassas, VA). Two xenograft cell
lines (4910 and 5310) were kindly provided by Dr. David James at
University of California, San Francisco. SNB19 and U251 cells
were grown in DMEM supplemented with 10% fetal bovine serum
(FBS) (Hyclone, Logan, UT) and 1% penicillin-streptomycin
(Invitrogen, Carlsbad, CA). Xenograft cell lines 4910 and 5310
were grown in RPMI-1640 medium supplemented with 10% FBS
and 1% penicillin-streptomycin. For hUCBSC, after obtaining
informed consent, human umbilical cord blood was collected from
healthy volunteers according to a protocol approved by the
Institutional Review Board. Cord blood was processed as
described previously by sequential Ficoll density gradient purifi-
cation [56]. Next, we selected cells using CD29 and CD81
markers as described previously. The nucleated cells were grown
in Mesencult medium (Stem cell Technologies, Vancouver,
Canada) supplemented with 20% FBS, 1% penicillin-streptomycin
and plated in 100 mm culture dishes. All the cells were grown at
37uC in an incubator with 5% CO2 atmosphere. Human
astrocytes were purchased from Sciencell Research Laboratories
(Carlsbad, CA) and were grown in astrocyte medium supplement-
ed with 2% FBS, 1% penicillin-streptomycin and 1% astrocyte
growth supplements (Sciencell Research Laboratories). For co-
culture experiments, hUCBSC/astrocytes and glioma cells were
cultured at a ratio of 1:4. Co-cultures of hUCBSC and SNB19,
hUCBSC and U251 were grown in DMEM; co-cultures of
hUCBSC and 4910, hUCBSC and 5310 were grown in RPMI-
1640; similarly co-cultures of astrocytes and SNB19, astrocytes
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4910, astrocytes and 5310 were grown in RPMI-1640.
For co-cultures with astrocytes, DMEM and RPMI-1640 were
supplemented with 1% astrocyte growth supplements. We
observed that 1% astrocyte growth supplements did not show
any effect on the growth of glioma cells (SNB19 and U251) and
xenograft cells (4910 and 5310), when they were grown alone.
Evaluation of cell death by LDH assay
The cytotoxic effect of hUCBSC on glioma cells was evaluated
by measuring lactate dehydrogenase (LDH) activity released in the
media 72 h after co-culture with hUCBSC using the CytoTox96
non-radioactive assay (Promega, Madison, WI). The experiment
was performed as per the manufacturer’s instructions and results
were quantified by measuring wavelength absorbance at 490 nm.
The experiment was performed three times (n=3) with 3 wells per
condition each time.
Measurement of cell proliferation by MTT assay
We examined cell proliferation in single cultures and co-cultures
of glioma cells with hUCBSC. The cultured glioma cells and co-
cultures with hUCBSC (100 mL medium) were plated in 96-well
microtiter plates at a final concentration of 0.5610
5 cells/well.
The MTT solution (5 mg/mL) was prepared in DMEM/RPMI
medium, and 10 mL were added to each well after treatment
period as described previously (56). Absorbance of converted dye
was measured at a wavelength of 570 nm with background
subtracted at 630 nm (Bio-Rad microplate reader). Data were
presented as percentage of MTT reduction as compared to control
cells. The experiment was performed three times (n=3) with 3
wells per condition each time.
RNA extraction and reverse transcription-based PCR
All primer sequences were determined using established human
GenBank sequences. Primer sequences were designed using
Primer3 (v.0.4.0) software. Total RNA was isolated from control
and hUCBSC-treated mice brains using Rneasy kit (Qiagen,
Valencia, CA) and quantity were determined by A260 measure-
ment. Total RNA was reverse transcribed into first strand cDNA
using Transcriptor First Strand cDNA Synthesis Kit (Roche,
Indianapolis, IN). Each cDNA was tested by running PCR using
GAPDH or b-actin primer as a control for assessing PCR
efficiency and for subsequent analysis by 2% agarose gel
electrophoresis. PCR amplification was performed using the
primer sets, amplified by 35 cycles (94uC, 1 min; 60uC, 1 min;
72uC, 1 min) of PCR using 20 pM of specific primers.
Primers used for PCR
XIAP:
Sense: 59ggccagactatgcccattta39
Antisense: 59cgaagaagcagttgggaaa39
b-Actin:
Sense: 59gtcgtaccactggcattgt39
Antisense: 59cagctgtggtggtgaagct39
Immunoblot analysis of proteins
Single and co-cultures of glioma cells, siXIAP transfected cells
or nude mice brain tissues were harvested and homogenized in
four volumes of homogenization buffer as described previously
[56]. Samples (40–50 mg of total protein/well) were subjected to
10–14% SDS-PAGE and transferred onto nitrocellulose mem-
branes. The following antibodies were used for Western blot
analysis: mouse anti-XIAP (1:5000; BD Biosciences, Franklin
Lakes, New Jersey), rabbit anti-AKT (1:1000; Cell Signaling
Technology Inc.), mouse anti-phospho-AKT (Ser
473) (1:1000; Cell
Signaling Technology Inc.), mouse anti-Bax (1:200; Santa Cruz
Biotechnology), mouse anti-Bad (1:200; Santa Cruz Biotechnolo-
gy), rabbit anti-Bcl-2 (1:200; Santa Cruz Biotechnology), rabbit
anti-cleaved caspase 3 antibody (1:1000; Abcam), rabbit anti-
TNF-a (1:1000; Cell Signaling), rabbit anti-TRAIL (1:1000;
Abcam), and rabbit anti-PARP (1:1000; Cell Signaling Technol-
ogy Inc.). Immunoreactive bands were visualized using chemilu-
minescence ECL Western blotting detection reagents (Amersham,
Piscataway, NJ). The reaction was detected using Hyperfilm-MP
autoradiography film (Amersham, Piscataway, NJ). Immunoblots
were stripped and redeveloped with GAPDH antibody [mouse
anti-GAPDH (1:1000; Santa Cruz Biotechnology)] to ensure equal
loading levels. Experiments were performed in triplicate. Values
for treated and untreated samples were compared using one-way
ANOVA. A p value of ,0.05 was considered significant.
Measurement of apoptosis and mitochondrial membrane
potential
Apoptosis and the integrity of the mitochondrial membrane
potential (Ym) were evaluated with the Vybrant Apoptosis Assay
Kit (Cat. No. V35116, Invitrogen, Carlsbad, CA). Apoptosis was
induced by co-culturing of glioma cells with hUCBSC for 3 days.
The concentration of the cells was adjusted to 5610
6 cells/mL in
culture medium. To 1 mL of cells, 4 mLo f1 0mM MitoTrackerH
Red working solution was added and stained for 30 min at 37uCi n
an atmosphere of 5% CO2. After incubation, cells were washed
with PBS and resuspended in 100 mLo f1 6 Annexin-binding
buffer. To this, 5 mL of Alexa FluorH 488 Annexin V was added
and the cells were incubated at room temperature for 15 minutes.
After the incubation period, 400 mL1 6 Annexin-binding buffer
was added, mixed gently and the samples were placed on ice. The
cells were analyzed by flow cytometry, measuring the fluorescence
emission at 530 nm and 585 nm using BD FACSCalibur (BD
Biosciences). In a similar manner, siXIAP transfected cells were
processed for the measurement of apoptosis and mitochondrial
membrane potential.
Determination of activity of caspase-3 and caspase-9
Caspase-3 and caspase-9 activity of cells were measured using
kits purchased from Millipore (Kankakee, IL). Control and treated
cells (co-cultures or siXIAP-transfected cells) were used for this
study. Treated and untreated cells were homogenized in 16 cell
lysis buffer and the homogenates were centrifuged at 10,000xg for
5 min at 4uC in a microcentrifuge. Using the 96-well plate micro
assay method, the supernatants were analyzed for caspase-3 or
caspase-9 activity levels. In a final volume of 100 mL, supernatants
(50 mg) of each test sample were incubated for 60 min at 37uCi n
the working solution containing Ac-DEVD-pNA, a synthetic
caspase-3 substrate. Absorbance was read at 405 nm in an ELISA
plate reader after a period of 60 min. Ac-DEVD-CHO inhibitor
was used for inhibitor studies. For experiments with inhibitor, the
samples were pre-incubated with Ac-DEVD-CHO inhibitor
(0.1 mM) for 10 minutes at room temperature before adding
caspase-3 substrate solution. Caspase-3 activity was calculated as
micromolar per gram of cells using a p-nitroaniline calibration
curve. The data were plotted as A405 versus time for each sample
and activity was calculated as pmol/min. In a similar manner, cells
were also processed for caspase-9 activity using Caspase-9
Substrate (Ac-LEHD-pNA) and Caspase-9 Inhibitor (Ac-LEHD-
CHO). For experiments with inhibitor, the samples were pre-
incubated with Ac-LEHD-CHO inhibitor (0.1 mM) for 10 minutes
at room temperature before adding caspase-9 substrate solution.
The experiments were repeated 3 times.
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The Institutional Animal Care and Use Committee of the
University Of Illinois College Of Medicine at Peoria approved all
surgical interventions and post-operative animal care. For the
intracerebral tumor model, U251 (1610
6 cells) and 5310 (8610
5
cells) tumor cells were intracerebrally injected into the right side of
the brain of the nude mice as described previously [57]. Seven
days after tumor implantation, the mice were injected with
hUCBSC towards the left side of the brain. The ratio of the
hUCBSC to glioma cells was maintained at 1:4. Three weeks after
tumor inoculation, six mice from each group were sacrificed by
cardiac perfusion with 4% formaldehyde in PBS, their brains were
removed, and paraffin sections were prepared. Sections were
stained with Hematoxylin & Eosin (H&E) to visualize tumor cells
and to examine tumor volume. The sections were blindly reviewed
by a neuropathologist and scored semiquantitatively for tumor
size. Whole-mount images of brains were also taken to determine
infiltrative tumor morphology. The average tumor area per section
integrated to the number of sections where the tumor was visible
was used to calculate tumor size and compared between controls
and treated groups. Immunoblot analyses and RT-PCR were done
on fresh brain tissues.
Immunohistochemical analysis
Brains of control and hUCBSC-treated mice were fixed in
formaldehyde and embedded in paraffin as per standard protocols.
Sections were deparaffinized and blocked in 1% BSA in PBS for
1 h, and the sections were subsequently transferred to primary
antibody diluted in 10% normal goat serum (1:100). Sections were
allowed to incubate in the primary antibody solution overnight at
4uC in a humidified chamber. Sections were then washed in 1%
BSA in PBS and placed in a solution with the appropriate
secondary antibody. The sections were incubated with the
secondary antibody for 1 h and visualized using a light/confocal
microscope. Transmitted light images were obtained after H&E
staining as per standard protocol to visualize the morphology of
the sections. Negative controls were maintained without primary
antibody or by using IgG fraction.
In situ terminal-deoxy-transferase mediated dUTP nick
end labeling (TUNEL) assay
A TUNEL apoptosis detection kit (Roche) was used for DNA
fragmentation fluorescence staining according to the manufactur-
er’s protocol. Briefly, glioma cells co-cultured with hUCBSC or
transfected with either siXIAP or scrambled vector (SV) or brain
sections were used for this study. Seventy-two hours after co-
culture or transfection, cells were fixed with 4% paraformaldehyde
in 0.1 M phosphate buffer (pH 7.4). Next, cells were incubated
with a reaction mix containing biotin-dUTP and terminal
deoxynucleotidyl transferase for 60 min. Fluorescein-conjugated
avidin was applied to the samples, which were then incubated in
the dark for 30 min. Positively stained fluorescein-labeled cells
were visualized and photographed using fluorescence microscopy.
For TUNEL assay of mice brain sections, a similar procedure was
followed after deparaffinization of the sections.
Construction of shRNA-expressing plasmid and
transfections
For this study, pSilencer
TM 4.1-CMV neo vector (Ambion,
Austin, TX) was used in the construction of the shRNA-expressing
vector. The Rat XIAP target sequence AACTGGACAGGTTG-
TAGATAT was used for the shRNA sequence. Inverted repeat
sequences were synthesized for XIAP. The inverted repeats were
laterally symmetrical, making them self-complimentary with a 9-
bp mismatch in the loop region. This 9-bp mismatch would aid in
the loop formation of the shRNA. Oligonucleotides were heated in
a boiling water bath in 66 SSC for 5 min and self-annealed by
slow cooling to room temperature. The resulting annealed
oligonucleotides were ligated to pSilencer at the BamHI and
HindIII sites. Glioma cells at 60–70% confluency in 100 mm
tissue culture plates were transfected with 10 mg of siRNA-
expressing plasmid constructs [scrambled vector (SV) or siXIAP]
using Fugene-HD as per the manufacturer’s instructions (Roche).
Following transfection, after 60 to 72 h depending on the cell line,
cell lysates were assessed for expression levels of different proteins
using western blot analysis as per standard protocol.
Fluorescent in situ hybridization (FISH) analysis
Serial 5 mm cross-sections were prepared on a cryostat, thaw
mounted on slides coated with 3-aminopropyltriethoxysilane
(Sigma, St. Louis, MO) and stored frozen until they were used
for in situ hybridization. Oligonucleotide antisense sequences with
a length of 48 bases were used as probes for the following genes:
XIAP Sense: AATGCTTTTGTTGTGGTGGAAAACTGA-
AAAATTGGGAACCCTGTGA
XIAP Antisense: TCACAGGGTTCCCAATTTTTCAGTT-
TTCCACCACAACAAAAGCATT
The oligonucleotides were labeled with FITC at 39 ends (Sigma-
Genosys, The Woodlands, TX) and were processed for FISH
analysis as described previously [58]. Briefly, slides were post-fixed
with 4% formaldehyde in PBS (pH 7.4) for 10 min, acetylated
(0.25% acetic anhydride in 0.1 M triethanolamine HCl, pH 8) for
10 min, and dehydrated with graded alcohols and chloroform.
They were then incubated overnight at 37uC with hybridization
buffer containing 200 ng/mL of each oligonucleotide probe. The
next day, slides were washed sequentially with 26 SSC (0.15 M
NaCl, and 15 mM sodium citrate, pH 7.0) for 5 min at room
temperature, 0.26SSC (1 h at 72uC in shaking water bath) and
0.26 SSC (5 min at room temperature) and then allowed for
detection of fluorescent-labeled probes using ELF 97 mRNA in situ
hybridization kit (Invitrogen, Carlsbad, CA). Finally, the slides
were counterstained with Hoechst 333342 (for visualization of cell
nuclei) and mounted using mounting medium. Visualization of
FISH signal was done with a fluorescence microscope (IX71
Olympus) and/or a confocal microscope (Olympus Fluoview).
Sections stained with sense probes served as controls, which do not
show any signal.
Statistical analysis
Quantitative data from cell counts, Western blot analysis, and
other assays were evaluated for statistical significance using one-
way analysis of variance (ANOVA). Data for each treatment group
were represented as mean 6 SEM and compared with other
groups for significance by one-way ANOVA followed by
Bonferroni’s post hoc test (multiple comparison tests) using Graph
Pad Prism version 3.02, a statistical software package. Results were
considered statistically significant at p less than 0.05.
Supporting Information
Figure S1 Growth inhibition of glioma cells by siXIAP. (A)
MTT assay of SV and siXIAP treatments of glioma cells. (B)
Cytotoxicity assay based on cytosolic LDH assay. (C) FACS
analysis results of glioma cells showing apoptotic cells as measured
by Annexin V. Each experiment was repeated 3 times. Error bars
indicate 6SEM. * significant at p,0.05.
Found at: doi:10.1371/journal.pone.0011813.s001 (5.45 MB TIF)
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siXIAP treatments. 40 mg of proteins were loaded onto 12–14%
gels, transferred onto nitrocellulose membranes, and probed with
respective antibodies. Immunoreactive bands were visualized using
chemiluminescence ECL Western blotting detection reagents and
the reaction was detected using Hyperfilm-MP autoradiography
film. Each experiment was repeated 3 times.
Found at: doi:10.1371/journal.pone.0011813.s002 (5.64 MB TIF)
Figure S3 Immunoblot analysis of proteins with cell lysates of
hUCBSC treatments at different time points. 40 mg of proteins
were loaded onto 12–14% gels, transferred onto nitrocellulose
membranes, and probed with respective antibodies. Immunore-
active bands were visualized using chemiluminescence ECL
Western blotting detection reagents and the reaction was detected
using Hyperfilm-MP autoradiography film. Each experiment was
repeated 3 times.
Found at: doi:10.1371/journal.pone.0011813.s003 (5.16 MB TIF)
Figure S4 Activity of caspases in siXIAP treatments. (A)
Caspase-3 activity in single and siXIAP transfected glioma cells.
(B) Caspase-9 activity in single and siXIAP transfected glioma
cells. Both these assays were done as described in Materials and
Methods. C3I = Caspase-3 Inhibitor (Ac-DEVD-CHO); C9I =
Caspase-9 inhibitor (Ac-LEHD-CHO). Each experiment was
repeated 3 times. Error bars indicate 6SEM. *Significant at
p,0.05.
Found at: doi:10.1371/journal.pone.0011813.s004 (8.74 MB TIF)
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